Over the next two years, Eli Lilly will be strengthening its efforts against counterfeiting with a $110 million investment in a new serialization program for its drug packages. The new program, the company’s most expensive and complex one, will oversee the stamping of unique codes and serial numbers on every drug package the company ships around the world.